Status:
UNKNOWN
Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients
Lead Sponsor:
Hospital Clinic of Barcelona
Conditions:
Acute Respiratory Distress Syndrome
Inflammation
Eligibility:
All Genders
18-99 years
Brief Summary
A continuous infusion of Dexmedetomidine (DEX) will be administered to 80 patients admitted to Critical Care because of signs of Respiratory Insufficiency requiring non-invasive ventilation. Measureme...
Detailed Description
It will be an observational study, with no randomization. To evaluate the influence of Dexmedetomidine on the time course of ARDS in patients admitted to the ICU unit because of severe respiratory dis...
Eligibility Criteria
Inclusion
- Patients with respiratory insufficiency criteria candidates to non-invasive ventilation techniques (high flow oxygen masks, non-invasive mechanical ventilation)
- SpO2 (at FiO2: 0.21) ≤ 93% equivalent to SaO2/FiO2≤442
- PaO2/ FiO2 \< 300
- Bilateral opacities consistent with pulmonary edema must be present and may be detected on CT or chest radiograph that must not be fully explained by cardiac failure or fluid overload, in the physician's best estimation using available information
Exclusion
- Affected by autoimmune disease
- Under specific therapy with Monoclonal Antibodies targeting inflammatory mediators
Key Trial Info
Start Date :
April 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04358627
Start Date
April 15 2020
End Date
June 30 2020
Last Update
April 24 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.